Featured Publications
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Research 1995, 55: 1946-55. PMID: 7728765.Peer-Reviewed Original ResearchConceptsHuman breast tumorsBreast tumorsPrimary human breast tumorsPoor patient prognosisSubset of tumorsEpidermal growth factor receptorGrowth factor receptorPatient prognosisImmunohistochemical stainingNeu/ErbBTumor samplesTumorsMonoclonal antibodiesHuman tumorsFactor receptorRelated receptorsReceptorsP185Polyclonal antibodiesAntibodiesErbBRelated epidermal growth factor receptorSubsetTyrosine phosphoproteinsPrognosis
2005
Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer
Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. Cancer Investigation 2005, 23: 483-487. PMID: 16203655, DOI: 10.1080/07357900500201301.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSingle-agent taxane therapyTaxane therapyP-HER2Clinical benefitBreast cancerClinical resistanceSingle-agent taxane chemotherapyUnique predictive informationChi-squared analysisTaxane chemotherapyClinical outcomesClinical progressionTaxane monotherapyHER2 statusClinical trialsPhosphorylated HER2Tumor specimensFunctional assessmentHER2TherapyMonoclonal antibodiesImmunohistochemistrySquared analysisProgression
2002
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Research 2002, 62: 6667-73. PMID: 12438265.Peer-Reviewed Original ResearchConceptsHER-2/neuCases of DCISDuctal carcinomaPrognostic indicatorNeu overexpressionHER-2/neu statusAdverse prognostic indicatorHormone receptor expressionPresence of calcificationIndicator of angiogenesisClinicopathological correlatesNeu levelsTumor sizeNeu expressionInvasive carcinomaHER-2Positivity rateReceptor expressionNeu statusBreast tumorigenesisDCISNeuCarcinomaMonoclonal antibodiesSignificant correlation
1998
Active signaling by Neu in transgenic mice
DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF. Active signaling by Neu in transgenic mice. Oncogene 1998, 17: 1877-1884. PMID: 9778054, DOI: 10.1038/sj.onc.1202091.Peer-Reviewed Original ResearchConceptsEndogenous epidermal growth factor receptorTransgenic micePhosphorylation state-specific antibodiesMammary tumorsRole of NeuEpidermal growth factor receptorMammary-specific promotersSignal transductionNeu transgenic miceGrowth factor receptorExpression of neuHuman breast cancerNeu activationFactor receptorNeu/Expression levelsMammary neoplasiaMammary lesionsBreast cancerTumor progressionNeuTumorsMiceMonoclonal antibodiesSpecific antibodies
1996
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.Peer-Reviewed Original ResearchConceptsHER-2/neuPrognostic indicatorBreast carcinomaInvasive breast carcinomaHER-2/ neuHuman breast tumorsFunctional assaysHuman breast carcinomaClinicopathological characteristicsPoor prognosisInvasive human breast tumoursLarge seriesBreast tumorsNeuMonoclonal antibodiesCarcinomaTumorsAntibodiesDifferent reportsOverexpressionReportAssaysPrognosis
1985
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Drebin J, Link V, Stern D, Weinberg R, Greene M. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41: 695-706. PMID: 2860972, DOI: 10.1016/s0092-8674(85)80050-7.Peer-Reviewed Original ResearchConceptsNIH 3T3 cellsAnchorage-independent growthAnti-p185 monoclonal antibodiesColony formationSoft agar colony formationAgar colony formationOncogene protein productGene productsNontransformed phenotypeProtein productsAntibody treatmentRas oncogeneDNA transfectionMonoclonal antibodiesNeu gene productSoft agarOncogenePhenotypeCellsP185P185 levelsNeuroblastoma linesUnrelated specificityControl antibodyNeu oncogene
1984
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
Drebin J, Stern D, Link V, Weinberg R, Greene M. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984, 312: 545-548. PMID: 6504162, DOI: 10.1038/312545a0.Peer-Reviewed Original ResearchConceptsNIH 3T3 cellsCell surface antigensCellular oncogenesAnimal cancer cellsNormal NIH 3T3 cellsMonoclonal antibodiesTumor-associated antigensVariety of antigensRelative molecular massCell surface determinantsNon-malignant cellsGenetic elementsDifferent histological originDNA transfectantsDNA transfectionMolecular massNeoplastic processAntibody reactivityNeoplastic cellsMalignant cellsHistological originAntigenIdentical antigensOncogeneCancer cells